Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil

Table 4 Variables associated with sustained virologic response by intention-to-treat analysis (n = 532)

	SVR (n = 493), % (n) or mean ± SD	Non-SVR (n = 39), % (n) or mean ± SD	P value
Age (yr)	56.85 ± 10.96	57.23 ± 12.61	0.811
Men/women	50.1% (247)/49.9% (246)	64.1% (25)/35.9% (14)	0.092
High-blood pressure	44.0% (214/486)	44.7% (17/38)	0.932
Type 2 diabetes	29.9% (146/488)	26.3% (10/38)	0.639
BMI (n = 442)	26.97 ± 5.01	27.59 ± 4.65	0.459
Dyslipidemia	20.0% (97/486)	31.6% (12/28)	0.089
Hypothyroidism	15.8% (77/486)	21.1% (8/38)	0.401
Psychiatric disorder	10.1% (49/484)	10.8% (4/37)	0.781
Previous alcohol use	18.6% (90/485)	31.6% (12/38)	0.051
HCV genotype
1	79.5% (392)	66.7% (26)	0.083
3	19.1% (94)	33.3% (13)
Other	1.4% (7)	0% (0)
Previous HCV treatment
None	45.5% (222)	56.8% (21)	0.409
Peg-IFN + RBV	46.7% (228)	37.8% (14)
Peg-IFN + PI	7.8% (38)	5.4% (2)
Liver fibrosis (Metavir classification)
F0 / F1	8.6% (42)	7.7% (3)	0.218
F2	13.6% (67)	10.3% (4)
F3	22.2% (109)	10.3% (4)
F4	55.6% (273)	71.8% (28)
Presence of cirrhosis
No	43.4% (214)	30.8% (12)	0.124
Yes	56.6% (279)	69.2% (27)
Liver-related complications
Ascites	20.3% (84/413)	25.7% (9/35)	0.451a
Esophageal varices	47.8% (197/412)	68.6% (24/35)	0.018a
Portal hypertensive bleeding	9.7% (40/412)	22.9% (8/35)	0.039a
Hepatic encephalopathy	8.5% (35/413)	28.6% (10/35)	0.001a
AST (U/L)	60.41 ± 44.53	74.51 ± 50.36	0.043a
ALT (U/L)	60.78 ± 55.75	76.19 ± 84.74	0.434
Total bilirubin (mg/dL)	1.12 ± 1.09	1.24 ± 0.95	0.384
Albumin (g/dL)	4.18 ± 2.73	3.70 ± 0.77	0.032a
Platelets (/mm3)	142.64 ± 78.05	131.10 ± 65.19	0.532
INR	1.17 ± 0.21	1.32 ± 0.40	0.023a
Creatinine (mg/dL)	1.23 ± 1.74	2.32 ± 3.77	0.694
Hemoglobin (g/dL)	13.74 ± 1.86	13.65 ± 2.34	0.798
Alpha-fetoprotein (ng/mL)	24.3 ± 107.22	13.20 ± 16.37	0.412
Child-Pugh classification (%)
A	72.0% (190)	56.0% (14)	0.124
B	25.8% (68)	44.0% (11)
C	2.3% (6)	0% (0)
Child-Pugh Score	5.91 ± 1.49	6.28 ± 2.01	0.109
MELD Score	9.98 ± 3.82	12.70 ± 4.81	0.001a
Dose of ribavirin (mg/kg/day)	12.11 ± 3.01	12.07 ± 2.98	0.946

^aP value < 0.05. Chi-square test, Fisher's exact test, and Mann-Whitney test. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; HCV: Hepatitis C virus; INR: International normalized ratio; ITT: Intention-to-treat; Peg-IFN: Pegylated-interferon; PI: Protease inhibitor (boceprevir or telaprevir); RBV: Ribavirin; SVR: Sustained virologic response.